DNMT3A R882 (Q27908043)

From Wikidata

Jump to navigation Jump to search

genetic variant

R882
R693
ARG882
ARG693

Language	Label	Description	Also known as
English	DNMT3A R882	genetic variant	R882 R693 ARG882 ARG693

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

human chromosome 2

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

25457241

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

25457243

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

positive therapeutic predictor for

medical condition treated

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/18

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

negative therapeutic predictor for

medical condition treated

acute myeloid leukemia

statement disputed by

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/11

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

positive diagnostic predictor for

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/112

DNMT3A Mutations in Acute Myeloid Leukemia

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/113

DNMT3A Mutations in Acute Myeloid Leukemia

negative diagnostic predictor for

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/110

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

positive prognostic predictor for

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/170

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

negative prognostic predictor for

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/50

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 5-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/64

DNMT3A Mutations in Acute Myeloid Leukemia

23 May 2022

https://civic.genome.wustl.edu/links/evidence/65

DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.

acute myeloid leukemia

determination method

CIViC evidence level B

CIViC 3-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/63

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

23 May 2022

https://civic.genome.wustl.edu/links/evidence/189

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/32

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27908043&oldid=2014797501"